Karuna Therapeutics Inc (KRTX)

Overview News Price History Option Chain Discussions Forecast

Karuna Therapeutics Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $329.9 pivot point. If it approaches the $329.5 support level, significant changes may occur.

Karuna Therapeutics Inc Stock (KRTX) Financials Data

Karuna Therapeutics Inc (KRTX) Net Income 2023

KRTX net income (TTM) was -$433.68 million for the quarter ending December 31, 2023, a -56.94% decrease year-over-year.

Karuna Therapeutics Inc (KRTX) Cash Flow 2023

KRTX recorded a free cash flow (TTM) of -$388.74 million for the quarter ending December 31, 2023, a -69.81% decrease year-over-year.

Karuna Therapeutics Inc (KRTX) Earnings per Share 2023

KRTX earnings per share (TTM) was -$11.72 for the quarter ending December 31, 2023, a -34.40% decline year-over-year.

Karuna Therapeutics Inc Stock (KRTX) Latest News

Strike While The Market Is Hot

Seeking Alpha

Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect

Benzinga

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst

Benzinga

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.

Initiated	Citigroup: Buy	Dec-12-23
Initiated	Deutsche Bank: Buy	Dec-12-23
Initiated	Wells Fargo: Overweight	Aug-22-23
Initiated	Morgan Stanley: Overweight	Jul-20-23
Initiated	Cantor Fitzgerald: Neutral	Mar-08-23
Initiated	UBS: Neutral	Jan-27-23
Initiated	Piper Sandler: Overweight	Jan-05-23
Initiated	Loop Capital: Buy	Nov-01-22
Initiated	SVB Leerink: Outperform	Jul-14-22
Initiated	Berenberg: Buy	Mar-31-22
Reiterated	Wedbush: Outperform	Jan-24-22
Initiated	JP Morgan: Overweight	Sep-30-21
Initiated	Citigroup: Buy	Aug-30-21
Initiated	Jefferies: Buy	Jul-28-21
Initiated	BofA Securities: Buy	Mar-22-21
Initiated	RBC Capital Mkts: Outperform	Feb-09-21
Initiated	Maxim Group: Buy	Nov-19-20
Reiterated	H.C. Wainwright: Buy	Aug-06-20
Initiated	H.C. Wainwright: Buy	May-28-20
Initiated	Oppenheimer: Outperform	Apr-28-20
Initiated	Guggenheim: Buy	Mar-31-20
Resumed	Wedbush: Outperform	Mar-24-20
Initiated	Mizuho: Buy	Feb-06-20
Initiated	JMP Securities: Mkt Outperform	Jan-09-20
Initiated	Stifel: Buy	Dec-19-19
Initiated	William Blair: Outperform	Dec-12-19
Initiated	Citigroup: Buy	Jul-23-19
Initiated	Goldman: Buy	Jul-23-19
Initiated	Wedbush : Outperform	Jul-23-19
Initiated	Wells Fargo: Outperform	Jul-23-19